華領醫藥GKA首創新藥華堂寧®正式發售實現首單處方銷售
格隆匯10月31日丨華領醫藥(2552.HK)在10月28日(上週五)舉行全球首創(first-in-class)新藥葡萄糖激酶激活劑(GKA)華堂寧®(多格列艾汀片)發售儀式。華領醫藥與商業化合作夥伴國藥控股、國藥物流和拜耳醫藥共同見證了華堂寧®的發車儀式。發售儀式當日,華堂寧®商業化後的首位患者在上海順利配方,實現了首單處方銷售。10月28日,全國首批約400家藥房可憑處方銷售。目前華堂寧®售價為420元人民幣一盒,每盒28片,1日2片,可供一位常規患者服用2周。目前,華領醫藥已組建可觸達全國經銷商的商務管理團隊,搭建了相對完善的藥品供應鏈體系,以支持產品的全面上市和業務拓展。此外,華領醫藥還自主開發了比較成熟的藥品經銷商管理體系(DMS),以滿足藥品從流通到使用的各個環節的需求,並且輔助未來的渠道創新數字化業務。中國擁有全球最多的糖尿病患者,目前患者數量已經達到1.4億,加上接近3億具有患病風險的人羣,糖尿病藥市場潛力巨大。華堂寧®上月底獲批後中,高盛、國元國際均表示看好公司前景,並給予“買入”評級。根據國元證券預測預計公司2023、2024年營業收入將達到2.3億元人民幣、15.1億元人民幣。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.